<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04193215</url>
  </required_header>
  <id_info>
    <org_study_id>V114-032</org_study_id>
    <secondary_id>V114-032</secondary_id>
    <nct_id>NCT04193215</nct_id>
  </id_info>
  <brief_title>V114 and Acute Otitis Media (V114-032/PNEU-ERA)</brief_title>
  <official_title>A Study of V114 and Acute Otitis Media in Children (PNEU-ERA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to evaluate V114 in the prevention of vaccine-type acute otitis&#xD;
      media (VT-AOM) and the safety of V114 with respect to the proportion of participants with&#xD;
      serious adverse events (SAEs) through completion of the study. The primary hypothesis is that&#xD;
      V114 is superior to no V114 in preventing VT-AOM as assessed by the incidence of VT-AOM.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 12, 2020</start_date>
  <completion_date type="Anticipated">June 12, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 12, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with a First Episode of Vaccine-Type Acute Otitis Media (VT-AOM) Caused by the Pneumococcal Serotypes Contained in V114</measure>
    <time_frame>Up to ~36 months</time_frame>
    <description>The number of participants with VT-AOM will be presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Serious Adverse Events</measure>
    <time_frame>Up to ~36 months</time_frame>
    <description>A serious adverse event (SAE) is an AE that results in death, is life-threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Vaccine-Related Serious Adverse Events</measure>
    <time_frame>Up to ~36 months</time_frame>
    <description>A serious adverse event (SAE) is an AE that results in death, is life-threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Discontinued the Study due to Serious Adverse Events</measure>
    <time_frame>Up to ~36 months</time_frame>
    <description>A serious adverse event (SAE) is an AE that results in death, is life-threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Died</measure>
    <time_frame>Up to ~36 months</time_frame>
    <description>The percentage of participants who died from any cause during the study will be assessed.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">4000</enrollment>
  <condition>Acute Otitis Media (AOM)</condition>
  <arm_group>
    <arm_group_label>V114</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive an intramuscular (IM) injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V114</intervention_name>
    <description>IM injection</description>
    <arm_group_label>V114</arm_group_label>
    <other_name>VAXNEUVANCEâ„¢</other_name>
    <other_name>Pneumococcal 15-Valent Conjugate Vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pediatric vaccines</intervention_name>
    <description>Standard of care vaccines administered according to the local recommended schedule.</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>V114</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Is healthy (based on a review of medical history and physical examination)&#xD;
&#xD;
          -  Is male or female, approximately 2 months of age, from 42 days to 90 days of age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Was born prior to 37 weeks of gestation.&#xD;
&#xD;
          -  Has a history of invasive pneumococcal disease (IPD) (positive blood culture, positive&#xD;
             cerebrospinal fluid culture, or other sterile site) or known history of other culture&#xD;
             positive pneumococcal disease.&#xD;
&#xD;
          -  Has a known hypersensitivity to any component of the pneumococcal conjugate vaccine&#xD;
             (PCV), any component of the licensed pediatric vaccines to be administered&#xD;
             concomitantly in the study, or any diphtheria toxoid-containing vaccine.&#xD;
&#xD;
          -  Has any contraindication to the concomitant study vaccines being administered in the&#xD;
             study.&#xD;
&#xD;
          -  Has external auditory canal atresia/stenosis.&#xD;
&#xD;
          -  Has a known or suspected impairment of immunological function.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>42 Days</minimum_age>
    <maximum_age>90 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chulalongkorn University ( Site 0008)</name>
      <address>
        <city>Bangkok</city>
        <state>Krung Thep Maha Nakhon</state>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phramongkutklao Hospital ( Site 0003)</name>
      <address>
        <city>Bangkok</city>
        <state>Krung Thep Maha Nakhon</state>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siriraj Hospital ( Site 0004)</name>
      <address>
        <city>Bangkok</city>
        <state>Krung Thep Maha Nakhon</state>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ramathibodi Hospital, Mahidol University ( Site 0009)</name>
      <address>
        <city>Rajthevee</city>
        <state>Krung Thep Maha Nakhon</state>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bhumibol Adulyadej Hospital ( Site 0013)</name>
      <address>
        <city>Sai Mai</city>
        <state>Krung Thep Maha Nakhon</state>
        <zip>10220</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Panyananthaphikkhu Chonprathan Medical Center ( Site 0014)</name>
      <address>
        <city>Pak Kret</city>
        <state>Nonthaburi</state>
        <zip>11120</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Faculty of Medicine Thammasat Univ. ( Site 0007)</name>
      <address>
        <city>Khong Luang</city>
        <state>Pathum Thani</state>
        <zip>12120</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince of Songkla University Faculty of Medicine ( Site 0005)</name>
      <address>
        <city>Hat Yai</city>
        <state>Songkhla</state>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maharaj Nakorn Chiang Mai Hospital ( Site 0001)</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiang Rai Prachanuchro Hospital-Pediatrics ( Site 0015)</name>
      <address>
        <city>Chiang Rai</city>
        <zip>57000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Srinagarind Hospital ( Site 0002)</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bamrasnaradura Infectious Disease Institute ( Site 0011)</name>
      <address>
        <city>Nonthaburi</city>
        <zip>11000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sappasit Prasong Hosptial-Pediatric ( Site 0016)</name>
      <address>
        <city>Ubon Ratchathani</city>
        <zip>34000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 9, 2019</study_first_submitted>
  <study_first_submitted_qc>December 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2019</study_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Otitis</mesh_term>
    <mesh_term>Otitis Media</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

